Analysts Anticipate MediciNova, Inc. (MNOV) to Announce ($0.11) EPS
Shares of MediciNova, Inc. (NASDAQ:MNOV) have earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price objective of $19.67 for the company and are predicting that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also given MediciNova an industry rank of 98 out of 255 based on the ratings given to related companies.
MNOV has been the subject of a number of recent analyst reports. ValuEngine raised MediciNova from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. BidaskClub raised MediciNova from a “hold” rating to a “buy” rating in a research report on Thursday, September 6th.
Shares of NASDAQ MNOV traded down $0.18 during trading on Friday, reaching $12.02. The company had a trading volume of 5,901 shares, compared to its average volume of 67,210. The stock has a market cap of $462.76 million, a price-to-earnings ratio of -37.63 and a beta of 0.32. MediciNova has a twelve month low of $5.66 and a twelve month high of $14.50.
MediciNova, Inc, a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction.
Featured Article: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.